OptimizeRx (OPRX) Gains from Sales and Divestitures (2023 - 2024)
OptimizeRx recorded quarterly Gains from Sales and Divestitures of $295018.0 in Q4 2024, up 107.97% quarter-over-quarter from $141859.0 in Q4 2023, and up 107.97% year-over-year from $141859.0 in Q1 2024.
OptimizeRx's Gains from Sales and Divestitures history runs 2 years deep, the most recent figure standing at $295018.0 for Q4 2024.
- In Q4 2024, Gains from Sales and Divestitures rose 107.97% year-over-year to $295018.0; the TTM figure through Dec 2024 stood at $295018.0 (up 107.97% YoY), while the FY2024 annual figure was $295018.0, up 107.97% from the prior year.
- Gains from Sales and Divestitures came in at $295018.0 for Q4 2024 at OptimizeRx, up from $141859.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $295018.0 in Q4 2024 to a low of $141859.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn |
| 10 | OptimizeRx | 101.31 Mn | 81.14 Mn | 15.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 295,018.00 |
| Dec 31, 2024 | 295,018.00 |
| Dec 31, 2023 | 141,859.00 |
| Dec 31, 2023 | 141,859.00 |